Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03005782
Title Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Regeneron Pharmaceuticals
Indications

lymphoma

Advanced Solid Tumor

Therapies

Cemiplimab + Fianlimab

Fianlimab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.